Study on hospital exemption clause of advanced therapy medicinal products in EU and its enlightenment to China
- VernacularTitle:欧盟先进疗法医药产品的医院豁免条款研究及对我国的启示
- Author:
Yifei WANG
1
;
Jinping XIE
1
;
Rong SHAO
1
Author Information
1. Institute of Regulatory Science for Medical Products，China Pharmaceutical University/NMPA Key Laboratory for Drug Regulatory Innovation and Evaluation，Nanjing 211198，China
- Publication Type:Journal Article
- Keywords:
advanced therapy medicinal products;
hospital exemption clause;
cell and gene therapy;
investigator initiated trials
- From:
China Pharmacy
2024;35(11):1285-1290
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To study the hospital exemption clause of advanced therapy medicinal products in the EU， and to provide policy recommendations for improving the regulatory system of cell and gene therapy （CGT） products in China. METHODS Through literature review and investigation of the official websites of EU member states， this study compared the differences in the application and implementation of the hospital exemption clause among member states from the perspectives of “non-conventional” definition， manufacturing standards， and pharmacovigilance requirements； the potential issues of hospital exemption clauses in practice were analyzed to propose policy recommendations based on the regulatory status of CGT in China. RESULTS & CONCLUSIONS EU has provided patients with rare diseases， who lack effective treatment or better therapy plans， with the opportunity to obtain new treatments through the hospital exemption clause， which has effectively improved the accessibility of medicines for patients. However， there still are certain disparities in the provisions of hospital exemption clause among EU member states. For instance， some member states have not explicitly defined “unconventional” circumstances； each member state has different requirements regarding production quality standards and pharmacovigilance requirement. Additionally， in the practical implementation of hospital exemption clause， issues such as poor transparency of information and a lack of certain restrictive conditions persist. Therefore， considering the current landscape and regulation of China’s CGT， it is recommended that China explore the clinical translational application of low-risk CGT in “unconventional” situations， strengthen the management of clinical translational application in terms of production quality standards and pharmacovigilance requirement. At the same time， it is necessary to further standardize the investigator initiated trials， and pay attention to the balance between clinical application and drug registration and marketing， thereby guiding the sustained and healthy development of China’s CGT.
